



**UNITED
MITOCHONDRIAL
DISEASE
FOUNDATION®**

HOPE. ENERGY. LIFE.

ANNUAL REPORT

July 1, 2010 - June 30, 2011



• *Mitochondrial Disease Affects Children and Adults* •



***The United Mitochondrial Disease Foundation
is bringing hope, energy, and life
to individuals and families
affected by mitochondrial disease.***

2010 - 2011 Annual Report

Contents

About the Foundation	4
Chairman's Message	5
Executive Director's Message	6
UMDF Accomplishments for July 1, 2010 - June 30, 2011	7
Research Grant Program & Results	8
2011 Research Grant Award Recipients	9
Financial Stewardship - How Each Dollar is Spent	10
Grant Funding by Year through 2011	11
UMDF Financial Statements & Independent Auditor's Report	12
UMDF National Office Staff	26
UMDF Scientific and Medical Advisory Board	27
UMDF Board of Trustees	28
UMDF Chapters, Groups, and Ambassadors	30

On the cover:

Savannah Greenawalt and Dr. Heather Baudet smile at one another at the Energy for Life Walkathon that was held in Charlotte, North Carolina on October 15, 2011. Both of them have mitochondrial disease.

About the Foundation...

In June of 2011, the United Mitochondrial Disease Foundation (UMDF) celebrated 15 years. The UMDF was founded by Charles A. Mohan, Jr. and his wife, Adrienne in 1996 through the merger of several smaller foundations established by those who lost loved ones to the disease. Starting as a volunteer organization located in a basement, the UMDF has grown into an internationally recognized non-profit organization. The UMDF staff responds to hundreds of inquiries each month about mitochondrial diseases and offers affected individuals and families information, resources, support, and referrals to experts in the mitochondrial field. The UMDF is represented nationally around the world by more than 60 chapters, groups, and ambassadors.

UMDF Mission

The UMDF mission is to promote research and education for the diagnosis, treatment and cure of mitochondrial disorders and to provide support to affected individuals and families. The UMDF is committed to increasing funding for mitochondrial disease research – to alleviate the suffering of thousands who have this debilitating, incurable, and often fatal disease and to develop a better understanding of the treatments for the many common illnesses and chronic conditions associated with it.

Research

Understanding mitochondrial disease has the potential to open a new world of knowledge, transforming medicine and cutting across all medical disciplines to uncover better treatments for a range of serious diseases. The UMDF has already achieved tremendous success in marshalling resources for new research and improving awareness and understanding of mitochondrial disease. Since its inception, the foundation has funded more than \$8 million in research, making it the leading non-governmental contributor of grants focused solely on mitochondrial disease. This research has led to a range of invaluable new breakthroughs. To learn more about UMDF research efforts, visit: www.umdf.org.

Family Support

The UMDF creates caring, supportive communities across the nation for adults, children and families suffering from mitochondrial disease through more than 60 local chapters, groups, and ambassadors. This allows UMDF members to network with other families and individuals and to talk about how to live with mitochondrial disease.

Information and Communication

The UMDF is committed to answering patients', policymakers' and the medical community's questions about mitochondrial disease – including important details about diagnosis, wide-ranging symptoms, and existing treatment.

Each year, the UMDF hosts the largest international research symposium dedicated to mitochondrial disease where the world's leading researchers meet with doctors, patients, and their families to exchange valuable knowledge. The UMDF also strives to build awareness of mitochondrial disease among physicians and healthcare providers by bringing the world's experts to them through its "Grand Rounds Program."

The UMDF advocates on the national level and empowers members to advocate on the local level regarding issues of medical funding and children's health issues, as well as social services for the medically fragile and disabled. In addition, the UMDF provides information about fundraisers and educational programs and maintains a website to provide the latest news and information about issues relating to mitochondrial disease research. The UMDF also publishes a quarterly newsletter that includes medical, advocacy, and support information.

Chairman's Message

This annual report will highlight one of the things that I am most proud of. For every dollar raised for the UMDF, .81 is used for programming. That means that 81% of our annual budget is spent on such items as research, education, support, and advocacy.

As this report highlights, in FY 2011, the Board of Trustees increased funding over FY 2010 levels by 50%. While our Finance Committee remained concerned about the economy, they were confident that our Energy for Life Walkathons, introduced in FY 2009/2010, would provide the financial resources that allowed us to increase our commitment to funding the research that our scientific and medical experts believe can bring us closer to better cures and treatments. The increase in research grant expenditures allowed the UMDF Grant Review Committee to fund five grants this fiscal year. At our annual symposium in 2011, I made a commitment that, barring any unforeseen downturn in the economy or the financial health of the UMDF, we would bring research grant funding back to the million dollar level.



W. Dan Wright
UMDF Chairman

I would also like to point out that thanks to a generous donation and a targeted development initiative, the UMDF was able to fund our first ever Clinical Fellowship. Anna-Kaisa Niemi, MD, PhD was the recipient of this two-year fellowship. This is a program that we want to continue. We believe that in funding this program to further educate those interested in mitochondrial medicine, we may be funding an individual who may discover a cure in the future.

One of the highlights in this past fiscal year was the first ever gathering between patients, families, and the scientific community for a session on clinical trials at our annual symposium. The information presented and shared is critical if we are to ever get to a cure. There is really no way to test the efficacy of many of the potential treatments that are currently in the pipeline and those still in planning without clinical trials.

Our programming budget also contains funding for all of the programs that are important to affected individuals and families – support, education, and advocacy. Aside from our one-of-a-kind symposium, I am proud to say that UMDF has provided 77 family support meetings and opportunities for patients and the medical community to interact; more than any other mitochondrial disease related organization. Some of these meetings included the attendance of medical experts who were brought to locations around the country to answer your questions and provide you with the latest information and potential treatments. In all, more than 4,000 people attended these information sessions. We also educated physicians, clinicians, and scientists by providing 19 Grand Rounds Programs across the United States. These programs are critical because they allow our experts in mitochondrial medicine to travel to hospitals in your communities and educate doctors, nurses, and other care givers about mitochondrial diseases and the latest information available.

These programming funds are also used on Capitol Hill. While we know that our measures in the House and Senate did not get introduced in 2010, the fruits of your hard work in contacting your elected officials have paid off. As a direct result of our legislation, The National Institutes of Health (NIH) began a dialogue with the UMDF and our Scientific and Medical Advisory Board about ways that items we ask for in the bill could be implemented. These very successful meetings with the NIH are expected to produce a workshop at the NIH, focusing on primary mitochondrial disease and ways to better collaborate regarding research. We are very excited about this; however, none of this would have happened without your help and the help of Senator Barbara Boxer (D-CA) and Rep. Jim McDermott (D-WA). We continue to work to have language calling for more research dollars inserted into the budget proposed to President Obama and within the research budgets at the Department of Defense.

I am also very proud to tell you that the UMDF remains below the national averages when it comes to expenditures. Fundraising expenses continue to decline with the implementation of our Energy for Life Walkathons across the nation. And, our administrative costs remain very low at 6% of budget.

As we move forward, the UMDF continues to position itself as the leader in research, education, and support for our community. We welcome the future; I can assure you that the UMDF will continue to rise to the challenges presented in the ever-changing world of mitochondrial medicine.

Executive Director's Message

William James, U.S. pragmatist philosopher and psychologist, said, "The great use of life is to spend it for something that outlasts it."

UMDF continues to strategically plan for the future, and with the support and guidance of the board of trustees, our members and supporters, is building a foundation that will continue to grow and move forward as we continue our quest toward treatments and cures for mitochondrial diseases.

Early in 1997, the young and fledgling UMDf recognized the lack of a support network for families suffering with mitochondrial disease. We realized then that we were in a unique position to have a positive impact on our Mito community. August 1, 1998, the first UMDf Support Group, Delaware Valley Support Group at Children's Hospital in Philadelphia, was formed.

From that first support group, UMDf grew to what is now the largest patient support network for mitochondrial disease in the world, represented by over 85 groups across the country, and is now being organized into geographic regions. The first pilot region, consisting of North and South Carolina, Tennessee, Georgia, Alabama and Florida, is being led by UMDf's new Regional Coordinator, Margaret Moore, who resides in Charlotte, NC.

Already, under this new structure, family support meetings have doubled, as have the requests for hospital grand rounds. UMDf continues to grow its speakers' bureau, enabling us to bring mitochondrial specialists to you. Plans are also being developed for mini-symposia in various states within the new region, and plans are also developing for the next region and regional coordinator.

UMDF represents the U.S. as a founding member of the International Mito Patients (IMP). This group, with representatives from Germany, Spain, France, Belgium, Italy and The Netherlands, will bring a global approach to connecting clinicians, researchers, and research and patients, and enhance communications and world-wide collaboration.

It was in 1997 that UMDf funded its first grant in the amount of \$30,000. Thirteen years and \$8 million later, we are the largest non-governmental funder of primary mitochondrial disease research in the world. This current grant cycle has the UMDf Grant Review Committee reviewing 44 submitted research proposals.

Successful political advocacy has created a heightened awareness among members of Congress which has spurred much needed discussion with many of the NIH Institutes. These discussions have resulted in the first NIH/UMDF Workshop on mitochondrial dysfunction. On March 8 and 9, 2012, UMDf organized and participated with 85 NIH intramural and extramural researchers to investigate and discuss the following goals: (1) share information related to primary mitochondrial disease among the NIH Intramural and Extramural Research Program Investigators, (2) develop and/or enhance systems to facilitate future collaboration and sharing of information, (3) survey obstacles, needs and priorities of primary mitochondrial diseases research, and (4) develop mechanisms to enhance translation of basic science discoveries to diagnostics and therapeutics. The results of this unprecedented workshop will be discussed at the June 2012 UMDf Symposium in Washington D.C.

Due to a generous grant from the Rembrandt Foundation, UMDf was able to fund its first Clinical Fellow in 2011. The UMDf clinical fellowship award is a one or two year award designed to support the training of a physician scientist who plans to practice clinical management of patients with mitochondrial disorders AND to conduct clinically (patient) oriented research in the field of mitochondrial medicine. The purpose of the award is to expand the number of clinicians and physician scientists practicing clinical management of patients with mitochondrial disorders and conducting clinically (patient) oriented research in the field of mitochondrial medicine. This year's recipient is Anna-Kaisa Niemi MD, PhD, from Stanford University, who will be working with Mito specialist, Dr. Greg Enns.

The North American Mitochondrial Disease Consortium (NAMDC) is one of 19 NIH funded consortia. The UMDf continues to support NAMDC as its patient advocacy member, along with their 13 clinical sites. NAMDC sites will be featured at the June 2012 UMDf Symposium and will be taking samples and enrolling patients into the NAMDC Patient Registry.

With your support, UMDf has come a long way; and with your continued support, UMDf will stay focused on its mission: "PROMOTING RESEARCH AND EDUCATION FOR THE DIAGNOSIS, TREATMENT AND CURE OF MITOCHONDRIAL DISORDERS AND PROVIDING SUPPORT TO AFFECTED INDIVIDUALS AND FAMILIES."

With your help, this is what we do every day; this is the reason we are here!



Charles A. Mohan, Jr.
**Chief Executive Officer/
Executive Director**

UMDF Accomplishments for July 1, 2010 - June 30, 2011

September 2010

More than 5,000 pieces of collateral were shipped from the UMDF national office to members around the nation as Awareness Week was celebrated. Seven Energy for Life Walkathons were held around the country raising \$331,841.

October 2010

UMDF's Grand Rounds Program held its 43rd meeting designed in a hospital setting to educate physicians about mitochondrial disease. Our Grand Rounds Program focuses on basic information, what symptoms physicians should look for, and how to treat affected patients.

December 2010

As a result of a workshop conducted by the National Institute of Environmental Health Sciences (NIEHS) and supported by the UMDF at a previous symposium, the NIEHS announced that it will provide \$2.5 million in this fiscal year to fund 6-8 grants for approved projects. The workshop was designed to explore the state of science and technology with experts in the field of mitochondrial physiology and function with the goal of developing biomarkers of mitochondrial dysfunction related to genetics and environmental exposures.

January 2011

The North American Mitochondrial Disease Consortium began enrolling affected individuals in its patient contact registry. UMDF serves as the liaison between NAMDC and the mitochondrial disease patient community.

February 2011

UMDF met with representatives of the National Institutes of Health (NIH) in the Office of U.S. Senator Barbara Boxer. NIH outlined current research into mitochondrial medicine and is seeking ways to help further research and collaboration among the institutes.

March 2011

UMDF held its 55th Patient and Family Support meeting for the fiscal year. During FY 2010/2011, the UMDF offered support and education to more than 4,100 people over the course of the year.

April 2011

The UMDF learned that the United States House of Representatives has included language in an appropriations bill that calls for additional research spending for mitochondrial diseases. The inclusion of this language comes after multiple visits to Capitol Hill by UMDF staff and board members.

May 2011

The NIH met with the UMDF in Bethesda, MD. The goal of the meeting was to define ways that the NIH and UMDF could work together to define research that is needed in mitochondrial medicine and to find ways that current researchers can collaborate across the NIH and externally. The outcome of the meeting was the idea of holding a workshop on the NIH campus later in 2011 or 2012. All 28 institutes at NIH were represented, as well as members of the UMDF's Board of Trustees and Scientific and Medical Advisory Board.

June 2011

UMDF celebrated its 15th anniversary by awarding \$500,000 in research grants and funding its first ever clinical fellowship at its annual Mitochondrial Medicine Symposium in Chicago, IL.

UMDF, for the first time ever, held a combined scientific and family session at its symposium to provide information on clinical trials. The session attracted media coverage in the Chicago Tribune and Los Angeles Times.

In conjunction with Edison Pharmaceuticals, the UMDF held a special seminar during the symposium for patients and clinicians interested in EPI-743. (EPI-743 is an Orphan Drug that is administered to subjects diagnosed with genetically confirmed inherited respiratory chain disease of the mitochondria that were either at end-of-life or at risk of blindness.)

UMDF Awarded \$500,000 in Research Towards a Cure for Mitochondrial Disease in 2011

Research Grants were awarded June 17, 2011 at the UMDF Annual Symposium in Chicago, IL

The United Mitochondrial Disease Foundation (UMDF) awarded a half of a million dollars to five researchers whose projects may lead to a cure for mitochondrial disease or better treatments for those who battle it. The research grant awards were presented at the UMDF's annual symposium, "Mitochondrial Medicine 2011: Chicago" which was held at the Renaissance Schaumburg Convention Center Hotel in Schaumburg, IL. This year's awards bring the total of amount of UMDF funded research to nearly \$8 million since 1996. The UMDF is the largest, non-governmental contributor of grants focused on mitochondrial disease research.

In 2011, the UMDF received 119 letters of inquiry from the scientific and medical community seeking funding for their proposed research projects. The UMDF Grant Review Committee asked 31 of the projects that were submitted for full proposals. The Grant Review Committee selected the top five proposals that they felt could provide the most promising research towards the diagnosis, treatment, and ultimate cure of mitochondrial disease.

Charles A. Mohan, Jr., UMDF Chief Executive Officer/Executive Director said, "We are pleased that we can provide this much money towards research that will hopefully lead to a cure for mitochondrial disease. It is truly our mission to support those affected by this devastating disease and find a cure for it."

A summary of the recipients, a brief description of their projects, and the award amounts are as follows.

2011 Research Grant Award Recipients



Brett Kaufman, PhD

Chairman's Award - \$120,000 for 2 yrs.

Brett Kaufman, PhD

Department of Animal Biology University of Pennsylvania, Philadelphia, PA

"Regulatory mechanisms governing TFAM-mediated mtDNA copy number control"

His research could lead to therapies that would increase the number of copies of normal mitochondrial DNA in patients with specific types of mitochondrial disease.



**Nicola
Brunetti-Pierri, MD**

Chairman's Award - \$120,000 for 2 yrs.

Nicola Brunetti-Pierri, MD

Telethon Institute of Genetics and Medicine

Fondazione Telethon, Rome, Italy

"Therapeutic Interventions for Pyruvate Dehydrogenase Deficiency."

He is seeking safe and effective treatments for a genetic condition that causes deficiencies of an important enzyme in the energy pathway of mitochondria.

2011 Research Grant Award Recipients



**Miguel
Garcia-Diaz, PhD**

Grant Award \$100,000 for 2 yrs.

Miguel Garcia-Diaz, PhD

Department of Pharmacological Sciences

Stony Brook University, Stony Brook, NY

“Deficiencies of tRNA maturation and the pathogenesis of mitochondrial diseases.”

He will study the regulation of mitochondrial transfer RNAs, molecules that are intrinsic to synthesis of the energy metabolism enzymes in mitochondria.



Ying Dai, MD, PhD

Grant Award \$80,000 for 2 yrs.

Ying Dai, MD, PhD

Department of Neurology

Beth Israel Deaconess Medical Center, Boston, MA

“Driving Selection Against Heteroplasmic Mitochondrial DNA Mutations by Enhancing Mitophagy.” He hopes to develop a mechanism whereby mitochondria with abnormal mutated mitochondrial DNA will be eliminated from cells, with the goal of restoring normal function.



Katie Clark, PhD

Grant Award \$80,000 for 2 yrs.

Katie Clark, PhD

Department of Zoology, Oregon State University, Corvallis, OR

“Identifying genes that prevent mitochondrial DNA deletions: a high-throughput approach using *Caenorhabditis elegans*.” Her research will provide insight into the mechanisms responsible for mitochondrial DNA deletion, a major cause of mitochondrial disease.

First Clinical Fellowship Training Award



**Anna-Kaisa
Niemi, MD, PhD**


The United Mitochondrial Disease Foundation is proud to announce a new Clinical Fellowship Program funded through generous donations from UMDF supporters. The \$75,000 award is for one year. It is given to a physician scientist who will practice clinical management of patients and who will conduct patient-oriented research in the field of mitochondrial medicine. The recipient of the 2011 award is Anna-Kaisa Niemi, MD, PhD from the Stanford University Medical Center.

“This program is designed to support the training of physician scientists who plan to train in the field of mitochondrial medicine,” said Charles A. Mohan, Jr., CEO and Executive Director, while making the award at the UMDF’s 2011 Symposium in Chicago. “We must encourage physicians and scientists to enter this field as we all recognize that there is a tremendous need for more physicians and scientists in the field.”

2011 Allocations of Each Dollar Raised

UMDF MAXIMIZES THE POWER OF EVERY DOLLAR DONATED

For every dollar donated to the UMDF over the last five years, \$.81 is allocated to research, education, and awareness; \$.13 is allocated to fundraising and \$.06 is allocated to administrative expenses.



This chart shows the allocation of funds for every dollar donated to the UMDF.

Research - .37 cents from every dollar donated is used for the UMDF Research Grant Program to fund the most promising research.


Education - .32 cents from every dollar donated is used for programs that benefit patients, families, and the medical community. These programs include our annual Symposium, the UMDF Grand Rounds and Family Meeting Programs, our educational materials (Mito 101 and the MitoFirst Handbook) and our support of newly diagnosed and current patients.

Awareness/Advocacy - .12 of every dollar is used to promote awareness of mitochondrial disease as well as support our advocacy efforts that are designed to secure additional funding for primary mitochondrial disease research.

Fundraising - .13 cents of every dollar is allocated towards fundraising. It should be noted that the entire "Energy for Life" training program was the result of a generous gift – so no donor dollars were used.

Administrative - .06 cents of every dollar is allocated to rent, utilities, UMDF operational costs.

Grant Funding through 2011



Since 1996, the UMDf has funded more than \$8 million in research projects aimed at providing patients with a faster diagnosis and better treatment options. Our ultimate objective is to find a cure for mitochondrial disease.

For a complete listing our funded research projects, visit www.umdof.org/fundedprojects.

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.**

**FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010
AND
INDEPENDENT AUDITOR'S REPORT**

TABLE OF CONTENTS

	<u>Page</u>
Independent Auditor's Report	13
Financial Statements	
Statements of Financial Position	14
Statements of Activities and Changes in Net Assets	15
Statements of Functional Expenses	16
Statements of Cash Flows	17
Notes to Financial Statements	18



Stelmack Dobransky & Eannace, LLC

Certified Public Accountants and Business Consultants

P.O. Box 62280
Pittsburgh, PA 15241-7280
E-mail: office@sdecpas.com
Tel: (724) 745-6600
Fax: (724) 745-7202

Joseph S. Stelmack, CPA

Joseph T. Dobransky, CPA

Vincent M. Eannace, CPA

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees of the
United Mitochondrial Disease Foundation, Inc.

We have audited the accompanying statements of financial position of the United Mitochondrial Disease Foundation, Inc. ("the Foundation") as of June 30, 2011 and 2010, and the related statements of activities, functional expenses and cash flows for the years then ended. These financial statements are the responsibility of the Foundation's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the United Mitochondrial Disease Foundation, Inc. as of June 30, 2011 and 2010, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Stelmack Dobransky & Eannace, LLC

STELMACK DOBRANSKY & EANNACE, LLC
McMurray, Pennsylvania

January 6, 2012

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.**

**STATEMENTS OF FINANCIAL POSITION
JUNE 30, 2011 AND 2010**

	2011	2010
<u>ASSETS</u>		
Cash and cash equivalents	\$ 564,165	\$ 368,726
Accounts receivable	16,900	22,987
Inventories	25,811	33,894
Investments (Note 3)	1,386,772	1,144,449
Prepaid expenses	15,773	28,597
Fixed assets - net (Note 4)	40,132	63,171
TOTAL ASSETS	\$ 2,049,553	\$1,661,824
<u>LIABILITIES AND NET ASSETS</u>		
LIABILITIES		
Accounts payable	\$ 207,854	\$ 213,936
Accrued liabilities	37,539	53,088
Grants payable (Note 5)	849,469	774,169
Deferred revenue	38,765	148,846
Total liabilities	<u>1,133,627</u>	<u>1,190,039</u>
NET ASSETS		
Unrestricted	593,399	204,176
Temporarily restricted (Note 7)	<u>322,527</u>	<u>267,609</u>
Total net assets	<u>915,926</u>	<u>471,785</u>
TOTAL LIABILITIES AND NET ASSETS	\$ 2,049,553	\$1,661,824

See Independent Auditor's Report and
Notes to the Financial Statements

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.
STATEMENTS OF ACTIVITIES AND CHANGES IN NET ASSETS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010**

	-----2011-----	-----2010-----			
	Unrestricted	Temporarily Restricted	Temporarily Unrestricted	Restricted	Total
PUBLIC SUPPORT AND REVENUE					
Support:					
Fundraising	\$1,469,512	\$ 144,870	\$ 1,614,382	\$ 63,619	\$1,278,883
Contributions	199,680	172,057	371,737	66,771	216,267
In honor of	127,879	0	127,879	82,501	82,501
In memory of	83,623	0	83,623	131,385	131,385
In kind	33,605	0	33,605	38,822	39,222
Grants	57,214	178,167	235,381	58,370	141,605
Cancellation of grants payable	43,501	0	43,501	27,734	27,734
Total support	2,015,014	495,094	2,510,108	1,703,572	1,917,597
Revenue:					
Symposium and seminars	219,625	2,000	221,625	219,158	219,158
Membership	21,161	0	21,161	30,538	30,538
Sales	11,214	0	11,214	7,787	7,787
Miscellaneous	0	0	0	901	901
Total revenue	252,000	2,000	254,000	258,384	258,384
Investment income	38,760	0	38,760	26,479	26,479
Net unrealized gain on investments	204,017	0	204,017	94,550	94,550
Net realized gain (loss) on investments	(120)	0	(120)	924	924
Net assets released from program restrictions	442,176	(442,176)	0	155,227	(155,227)
Total support and revenue	2,951,847	54,918	3,006,765	2,239,136	2,297,934
FUNCTIONAL EXPENSES					
Program services:					
Research	748,459	0	748,459	420,005	420,005
Public awareness	242,315	0	242,315	301,434	301,434
Education/member support	830,930	0	830,930	755,041	755,041
Total program services	1,821,704	0	1,821,704	1,476,480	1,476,480
Supporting services:					
Administrative and general	130,923	0	130,923	149,268	149,268
Fundraising	609,997	0	609,997	695,297	695,297
Total supporting services	740,920	0	740,920	844,565	844,565
Total expenses	2,562,624	0	2,562,624	2,321,045	2,321,045
CHANGES IN NET ASSETS	389,223	54,918	444,141	(81,909)	(23,111)
NET ASSETS - Beginning of year	204,176	267,609	471,785	286,085	208,811
NET ASSETS - End of year	\$ 593,399	\$ 322,527	\$ 915,926	\$ 204,176	\$ 267,609
					\$ 471,785

See Independent Auditor's Report and Notes to the Financial Statements

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.**
**STATEMENTS OF FUNCTIONAL EXPENSES
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010**

	-----2011-----				-----2010-----				
	Program Services	Supporting Services	Admin. & General	Fundraising	Program Services	Supporting Services	Admin. & General	Fundraising	
	Research	Public Awareness	Education Member Support	2011 Total	Research	Public Awareness	Education Member Support	2010 Total	
Bad debt expense	0	\$ 0	0	\$ 0	0	\$ 0	0	\$ 583	
Bank fees	0	0	2,443	17,600	0	0	3,549	18,465	
Chapter support	0	503	49,082	51,251	0	769	14,668	17,855	
Depreciation	2,312	4,661	16,036	34,186	4,382	8,217	24,652	59,071	
Fundraising	0	68	5,378	230,877	0	6,477	4,604	284,390	
Research grants awarded	640,000	0	0	640,000	315,348	0	0	315,348	
Insurance	659	1,357	3,124	2,789	651	1,402	2,987	2,621	
Licenses and fees	550	1,011	2,755	3,090	342	641	1,971	6,622	
Meetings	1,510	199	247,214	21,627	7,108	211	212,391	31,904	
Merchandise costs	0	0	0	12,913	0	4,041	315	6,245	
Miscellaneous	0	799	5,363	1,079	168	459	5,164	12,852	
Payroll taxes	6,248	8,672	30,204	18,480	5,756	8,922	29,821	21,238	
Physician's education program	0	0	3,300	0	0	11,077	0	0	
Postage and shipping	159	1,006	2,805	8,788	56	200	5,542	8,590	
Printing	4,455	1,955	5,647	14,849	30	56	8,105	6,370	
Professional fees	600	1,125	3,637	3,028	765	1,434	6,197	2,199	
Promotion and marketing	0	79,193	455	836	0	116,821	330	40	
Rent	5,607	11,137	33,407	17,072	5,813	11,608	30,939	10,626	
Recruiting and relocation	0	419	0	1,097	0	0	0	1,686	
Salaries and benefits	80,530	124,081	384,571	245,402	72,970	121,437	370,752	260,284	
Repairs and maintenance	3,209	3,781	13,432	3,575	2,798	4,951	16,116	7,591	
Staff development	0	0	0	0	0	0	593	0	
Supplies	49	118	5,514	1,449	128	233	3,179	772	
Telephone	1,170	2,230	12,976	3,389	1,305	2,478	8,882	3,778	
Travel	1,401	0	3,587	2,612	2,385	0	4,284	3,509	
Total functional expenses \$	748,459	\$ 242,315	\$ 830,930	\$ 609,997	\$ 2,562,624	\$ 420,005	\$ 301,434	\$ 755,041	\$ 149,268
									\$ 695,297

See Independent Auditor's Report and Notes to the Financial Statements

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.**

**STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010**

	2011	2010
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	\$ 444,141	\$ (23,111)
Adjustments to reconcile change in net assets provided by (used in) operating activities:		
Depreciation	34,186	59,071
Realized (gain) loss on sale of investments	120	(924)
Unrealized (gain) on investment	(204,017)	(94,550)
Changes in assets (increase)/decrease:		
Contribution receivable	0	10,000
Accounts receivable	6,087	(9,055)
Inventories	8,083	(6,952)
Prepaid expenses	12,824	747
Changes in liabilities (decrease)/increase:		
Accounts payable	(6,082)	(9,259)
Accrued expenses	(15,549)	20,177
Grants payable	75,300	(248,908)
Deferred revenue	(110,081)	23,517
Net cash provided by (used in) operating activities	<u>245,012</u>	<u>(279,247)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of equipment	(11,147)	(21,345)
Purchase of investments	(43,330)	(58,351)
Proceeds on sale of investments	4,904	32,980
Net cash provided by (used in) investing activities	<u>(49,573)</u>	<u>(46,716)</u>
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	195,439	(325,963)
CASH AND CASH EQUIVALENTS – Beginning of year	<u>368,726</u>	<u>694,689</u>
CASH AND CASH EQUIVALENTS – End of year	<u>\$ 564,165</u>	<u>\$ 368,726</u>
SUPPLEMENTAL INFORMATION		
Interest paid	\$ 0	\$ 0
Income taxes paid on unrelated business income	\$ 0	\$ 0

See Independent Auditor's Report and
Notes to the Financial Statements

**UNITED MITOCHONDRIAL
DISEASE FOUNDATION, INC.**

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010**

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization and Nature of Activities

The United Mitochondrial Disease Foundation, Inc. (“the Foundation”) was organized on April 28, 1995, and is the result of a merger between a number of specific Mitochondrial disease organizations to form a larger, more cohesive united foundation representing all mitochondrial diseases and all sufferers, adult and children alike. The Foundation’s mission is to promote research for cures and treatments of mitochondrial disorders and to provide support to affected families.

Basis of Accounting

The accompanying financial statements are prepared on the accrual basis of accounting, and accordingly, reflect all significant receivables, payables, and other liabilities.

Financial Statement Presentation

The Foundation’s financial statements are prepared in accordance with FASB ASC 958-210 (formerly Statement of Financial Accounting Standards (SFAS) No. 117, “Financial Statements of Not-for-Profit Organizations”). Under FASB ASC 958-210, the Foundation is required to report information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets and permanently restricted net assets.

Contributions

Contributions received are recorded as unrestricted or temporarily restricted net assets depending on the existence or nature of any donor restrictions.

Cash and Cash Equivalents

For purposes of the Statement of Cash Flows, the Foundation considers all highly liquid investments with an initial maturity of one year or less to be cash equivalents. For the years ended June 30, 2011 and 2010, the Foundation had no noncash investing or financing activities for cash flow purposes.

Estimates

Management uses estimates and assumptions in preparing financial statements. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported revenues and expenses. Actual results could differ from those estimates.

Inventories

Inventories consist of merchandise and are stated at the lower of cost (first-in-first-out) or market.

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Investments

The Foundation records investments in accordance with FASB ASC 958-320 (formerly SFAS No. 124, "Accounting for Certain Investments Held by Not-for-Profit Organizations"). Under FASB ASC 958-320, investments are presented at their fair value, which is established using the fair value hierarchy (See Note 3).

Fixed Assets

Fixed assets are recorded at cost and depreciated using the straight-line method over estimated useful lives of 5 to 7 years. Depreciation expense, totaling \$34,186 and \$59,071 for the years ended June 30, 2011 and 2010, respectively, is allocated to the various activities based on usage.

Revenue and Expense Recognition

Income from membership dues and program service fees are deferred and recognized over the periods to which the specific types of income relate. Costs and expenses related to such activities are also deferred as prepaid expenses and recognized in the period when the programs are held.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities and changes in net assets. Accordingly, certain costs have been allocated among the programs and supporting services benefited.

Income Tax Status

The Foundation is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. However, income from certain activities not directly related to the Foundation's tax-exempt purpose is subject to taxation as unrelated business income. For the years ended June 30, 2011 and 2010, the Foundation had no such income. In addition, the Foundation qualifies for the charitable contribution deduction under Section 170(b)(1)(A) and has been classified as an organization that is not a private foundation under Section 509(a)(1).

The Foundation adopted the accounting standard for uncertain tax positions as of July 1, 2009. The standard requires a two-step approach to recognizing and measuring uncertain tax positions accounted for in accordance with the asset and liability method. The first step is to evaluate the tax position for recognition by determining whether evidence indicates that it is more likely than not that a position will be sustained if examined by a taxing authority. The second step is to measure the tax benefit as the largest amount that is 50% likely of being realized upon settlement with a taxing authority. The adoption of this standard did not have a material impact on the Foundation's financial statements.

The Forms 990, *Return of Organization Exempt from Income Tax*, of the Foundation are subject to examination by the IRS, generally for three years after they were filed.

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Continued

Concentration of Credit Risk

Financial instruments which potentially subject the organization to a concentration of credit risk consist principally of cash, temporary cash investments and marketable securities. The cash, temporary cash investments and marketable security accounts of the organization are maintained at high quality financial institutions. At times such accounts may be in excess of FDIC insurance limits, but pose no significant concentration of credit risk.

Changes in Presentation of Comparative Statements

Certain prior year amounts have been reclassified to conform to the current year presentation.

Subsequent Events

Management has evaluated subsequent events through January 6, 2012, the date on which the financial statements were available to be issued.

2. DESCRIPTION OF MAJOR PROGRAMS

Research

The Foundation is committed to finding treatments and cures for mitochondrial disease and believes research is the path to success. Since 1996 the Foundation has been providing research grants in order to advance the cause of research into mitochondrial disease.

Public Awareness

The Foundation is raising awareness among clinicians, pediatricians, general practitioners, and other allied health professionals through exhibition at annual medical meetings and its "Grand Rounds" lecture series at hospitals around the country. The Foundation has also produced "Mito 101" an interactive CD to educate primary care physicals and pediatricians about mitochondrial diseases and "MitoFirst" a handbook for newly diagnosed patients and their physicians.

Education/Member Support

The Foundation creates caring, supportive communities across the nation for adults, children and families suffering from mitochondrial disease through their local chapters and affiliated groups and ambassadors. This allows foundation members to network with other families and individuals to talk about mitochondrial disorders. The Foundation also keeps members updated with the latest treatment advances and information through a quarterly newsletter.

3. INVESTMENTS

Investments at June 30, 2011 are summarized as follows:

	Cost Basis	Gross Unrealized Gains	Gross Unrealized Losses	Fair Market Value
Mutual funds	\$1,214,653	\$172,119	\$0	\$1,386,772

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

3. INVESTMENTS, Continued

Investments at June 30, 2010 are summarized as follows:

	Cost Basis	Gross Unrealized Gains	Gross Unrealized Losses	Fair Market Value
Mutual funds	\$1,176,348	\$ 0	\$ (31,899)	\$1,144,449

Fair Value Measurements

Generally accepted accounting principles (GAAP) establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy consists of three broad levels: Level 1 inputs consist of unadjusted quoted prices in active markets for identical assets and have the highest priority, Level 2 inputs consist of observable inputs other than quoted prices for identical assets, and Level 3 inputs have the lowest priority. The Company uses appropriate valuation techniques based on the available inputs to measure the fair value of its investments. When available, the Company measures fair value using Level 1 inputs because they generally provide the most reliable evidence of fair value. The fair values of the mutual funds are Level 1 inputs. No Level 2 or Level 3 inputs were available to the Company.

4. FIXED ASSETS

Fixed assets are summarized as follows at June 30:

	2011	2010
Furniture and fixtures	\$ 57,675	\$ 57,675
Computer equipment	273,035	277,932
Leasehold improvements	5,225	5,225
Total fixed assets	335,935	340,832
Less accumulated depreciation	295,803	277,661
Fixed assets – net	\$ 40,132	\$ 63,171

5. GRANTS PAYABLE

Grants authorized but unpaid at year end are reported as liabilities in accordance with FASB ASC 958-605 (formerly SFAS No. 116, "Accounting for Contributions Received and Contributions Made").

In May 2005, the Board of Trustees approved future research grants totaling \$1,018,489 to be paid to qualified recipients from the years 2005 through 2007. During the year ended June 30, 2011, \$519 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2006, the Board of Trustees approved future research grants totaling \$1,025,021 to be paid to qualified recipients from the years 2006 through 2008. During the year ended June 30, 2011 \$36,315 of these grants were cancelled. As of June 30, 2011, \$11,400 was unpaid.

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

5. GRANTS PAYABLE, Continued

In May 2007, the Board of Trustees approved future research grants totaling \$1,150,637 to be paid to qualified recipients from the years 2007 through 2009. During the year ended June 30, 2011 \$683 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2008, the Board of Trustees approved future research grants totaling \$1,025,080 to be paid to qualified recipients from the years 2008 through 2010. During the year ended June 30, 2011, \$5,983 of these grants were cancelled. As of June 30, 2011, there were no amounts unpaid.

In May 2009, the Board of Trustees approved future research grants totaling \$412,661 to be paid to qualified recipients from the years 2009 through 2011. As of June 30, 2011, \$70,395 was unpaid.

In May 2010, the Board of Trustees approved future research grants totaling \$315,348 to be paid to qualified recipients from the years 2010 through 2012. As of June 30, 2011 \$127,674 was unpaid.

In May 2011, the Board of Trustees approved future research grants totaling \$640,000 to be paid to qualified recipients from the years 2011 through 2013. As of June 30, 2011, all grants awarded in the current fiscal year were unpaid.

6. RETIREMENT PLANS

403(b) Tax Deferred Annuity Plan

The Company has a 403(b) Tax Deferred Annuity Plan covering substantially all of its employees. Employees may make voluntary pre-tax contributions to the plan subject to maximums allowed by the Internal Revenue Code. The Company does not match any of the contributions.

SEP-IRA Plan

The Company also has established a SEP-IRA retirement plan for substantially all employees. Contributions are determined by management and are totally discretionary. Contributions amounted to approximately \$28,000 and \$21,000 for the years ended June 30, 2011 and 2010, respectively.

7. NET ASSETS

Temporarily restricted net assets at June 30, 2011 and 2010 are available for the following purposes:

	2011	2010
Research	\$322,527	\$267,609
	\$322,527	\$267,609

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

8. OPERATING LEASE

The Foundation leases office space under an operating lease agreement that expires October 2012. The Foundation leases a copier under an operating lease agreement that expires November 2011. The Foundation also leases a postage machines under an operating lease agreement that expires June 2014. The future minimum rental payments required under these lease agreements are:

<u>Year Ended</u> <u>June 30,</u>	<u>Amount</u>
2012	\$ 65,980
2013	18,462
2014	2,280
Thereafter	<u>0</u>
Total	<u>\$ 86,722</u>

Rental expense amounted to \$67,033 and \$60,634 for the years ended June 30, 2011 and 2010, respectively.

9. CONTRIBUTED SERVICES

FASB ASC 958-605 requires contributed services to be recognized if the services received create or enhance nonfinancial assets or require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by volunteers. The Foundation receives such services from community members who volunteer to provide video production, website development and accounting services. The value of these services was calculated as \$33,605 and \$39,222 for the years ended June 30, 2011 and 2010, respectively, and is included in the accompanying Statements of Activities as revenue and expense.

10. CHAPTERS

In addition to the national office of the United Mitochondrial Disease Foundation, Inc., local chapters have also been formed throughout the United States. These chapters include:

- Ohio Chapter
- Delaware Valley Chapter
- Southern California Chapter
- Kansas City Chapter
- New England Chapter
- Arizona Chapter
- New York Metro Chapter
- Indiana Chapter
- Atlanta Chapter
- Chicago Chapter
- Houston Chapter
- Central Ohio Chapter
- Carolina Foothills Chapter
- Minneapolis-St. Paul Chapter
- Middle Tennessee Chapter
- D/C/Baltimore/Northern Virginia Chapter

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

10. CHAPTERS, Continued

Each chapter is required to file an application for their own employer identification number, abide by their signed chapter affiliation agreement and by-laws and to provide the national office their monthly chapter finance report. The Foundation has received a group exemption under 501(c)(3) of the Internal Revenue Code, and accordingly, will file a group tax return for the chapters. The primary purpose of the chapters is to provide a support network and conduct charitable fundraising activities for the Foundation. The chapters meet the requirements for consolidation and accordingly, their balances are included in the accompanying financial statements.

The Statements of Financial Condition include the cash balances of each chapter as of June 30 as follows:

	<u>2011</u>	<u>2010</u>
Ohio Chapter	\$ 4,496	\$ 32,449
Delaware Valley Chapter	209	1,080
Kansas City Chapter	5,663	1,963
New England Chapter	1,000	1,000
Indiana Chapter	6,619	6,616
Atlanta Chapter	1,078	1,994
Chicago Chapter	1,397	1,399
Houston Chapter	13,772	17,122
Carolina Foothills Chapter	5,362	3,536
Minneapolis-St. Paul Chapter	6,606	4,296
Central Ohio Chapter	0	1,326
Middle Tennessee Chapter	1,654	693
D/C/Baltimore/Northern Virginia Chapter	7,728	7,339

(Continued)

UNITED MITOCHONDRIAL DISEASE FOUNDATION, INC.
NOTES TO FINANCIAL STATEMENTS
FOR THE YEARS ENDED JUNE 30, 2011 AND 2010

10. CHAPTERS, Continued

The Statements of Activities and Changes in Net Assets for the years ended June 30, 2011 and 2010 includes the activity for each chapter as follows:

	-----2011-----		-----2010-----	
	Revenue	Expenses	Revenue	Expenses
Ohio Chapter	\$ 132,575	\$ 15,146	\$ 135,838	\$ 24,824
New England Chapter	10,583	3,655	65,182	9,001
Southern California Chapter	6,483	2,393	22,045	5,970
Delaware Valley Chapter	46,855	8,202	120,647	30,841
Arizona Chapter	61,189	5,351	980	43
New York Metro Chapter	10,055	4,724	21,493	5,317
Kansas City Chapter	30,741	3,555	14,354	1,051
Indiana Chapter	54,587	8,624	30,984	5,530
Atlanta Chapter	153,392	37,449	188,955	65,978
Chicago Chapter	71,880	15,464	51,994	8,237
Houston Chapter	197,507	45,820	117,517	25,380
Central Ohio Chapter	4,715	7	39,481	18,571
Carolina Foothills Chapter	95,033	10,874	24,642	690
Minneapolis-St. Paul Chapter	70,482	7,554	51,017	6,962
Middle Tennessee Chapter	83,703	12,660	32,940	5,372
D/C/Baltimore/Northern Virginia Chapter	40,983	21,810	39,460	13,394
Total	\$ 1,070,763	\$ 203,288	\$ 957,529	\$ 227,161

(Concluded)

UMDF National Office Staff

Charles A. Mohan Jr., CEO/Executive Director

Mark Campbell, Chief Financial Officer

Kara Strittmatter, Director of Member Services

Clifford Gorski, Director of Communications

Marian Weil, Director of Development

Tania Hanscom, Special Events Coordinator

Scott Precopia, IT Manager

Jean Bassett, Research Grants Coordinator

Alison Cooley, Communications Assistant

Don Gielas, Grant Writer

Justin Lantz, IT Multimedia Associate

Rachel Mazur, Special Events Associate

Donna Nameth, Data Entry Manager

Melinda O'Toole, Member Services Associate

Janet Owens, Executive Administrative Assistant

Barbara Podowski, Administrative Assistant

Nicole Shanter, Special Events Associate

UMDF MISSION

To promote research and education for the diagnosis, treatment, and cure of mitochondrial disorders and to provide support to affected individuals and families.

UMDF Scientific and Medical Advisory Board

Carlos Moraes, PhD - Chairman

University of Miami
Miami, FL

Russell Saneto, DO, PhD - Secretary

Seattle Children's
Seattle, WA

Laurence Bindoff, MD

Haukeland University Hospital
Bergen, Norway

Rod Capaldi, PhD

University of Oregon
Eugene, OR

David Chan, PhD

California Institute of Technology
Pasadena, CA

Patrick Chinnery, PhD, MRCP

University of Newcastle upon Tyne
Newcastle upon Tyne, UK

William Copeland, PhD

National Institute of Environmental
Health Sciences (NIEH)
Research Triangle Park, NC

Greg Enns, MB, ChB

Stanford University
Stanford, CA

Michio Hirano, MD

Columbia University Medical Center
New York, NY

Edward McKee, PhD

Indiana University School of Medicine
South Bend, IN

Vamsi Mootha, MD

Harvard Medical School
Boston, MA

Fernando Scaglia, MD

Baylor College of Medicine
Houston, TX

Peter Stacpoole, PhD, MD

University of Florida
Gainesville, FL

Mark Tarnopolsky, MD, PhD, FRCP(C)

McMaster University
Hamilton, Ontario, Canada

Massimo Zeviani, MD

National Neurological Institute C. Besta
Milano, Italy

UMDF Board of Trustees



Dan Wright
Chairman
Dallas, TX



Sharon Shaw
Vice Chairman
Scottsdale, AZ



Marty Lyman
Secretary
Cuyahoga Falls, OH



Richard Kubach
Treasurer
King of Prussia, PA



Chuck Mohan
Chair Emeritus
Pittsburgh, PA



Bruce Cohen, MD
Trustee
Akron, OH



Gerald Cook, Esq.
Trustee
Pittsburgh, PA



Linda Cooper
Trustee
Orange, CA




John DiCecco
Treasurer
Westerville, OH



Amy Goldstein, MD
Trustee
Pittsburgh, PA

UMDF Board of Trustees



Leslie Boyer Heilman, JD
Trustee
Pittsburgh, PA



Richard Leach
Trustee
Washington, D.C.



Molly Auth Manning
Trustee
Boston, MA



Carlos Moraes, PhD
Trustee
Miami, FL



Tyler Reimschisel, MD
Trustee
Nashville, TN



Joseph Rice
Trustee
Mount Juliet, TN



Philip Yeske, PhD
Trustee
Pittsburgh, PA



Darcy Zehe
Chapter Liaison
Cleveland, OH



Howard Zucker, JD, MD
Trustee
Cliffside Park, NJ

UMDF Chapters, Mito Groups, and Ambassadors

*To reach an Ambassador, simply e-mail ambassadors@umdf.org.
When sending the e-mail, please include the leader's name
or city/state in the subject line for us to better serve your needs.*

★ Stars Denote Chapters

ALABAMA

North Alabama Mito Group
Contact: Margie Slep,
Huntsville

ARIZONA

Ambassador:
Contact: Gina Blair, Peoria

ARKANSAS

Ambassador:
Lacie Moore, Rogers

CALIFORNIA

★California Chapter
President: Norma Gibson
E-mail: CalChapter@umdf.org
Ambassador:
Cheryl Burge, Beaumont

DELAWARE

Ambassador:
Contact: Judy Weeks, Dover

FLORIDA

Central Florida Mito Group
Contact: Amber Ferrell,
Gainesville
Contact: Jennifer Slauter,
Orlando
Ambassadors:
Sophie Szilagy, North East Florida
Holly Schneider, Coconut Creek
★Atlanta Area Chapter
President: Chris Swinn
E-mail: ATLchapter@umdf.org
Atlanta Chapter Support
Contact: Shelly Lorenzen,
Sugar Hill

Ambassadors:
Hannah Bossie, Athens
Gail LaFramboise,
West Central Georgia

HAWAII

Ambassador:
Kimo Phan, Honolulu

IDAHO

Idaho Mito Group
Contact: Jennifer Pfefferle, Boise

INDIANA

★Indiana Chapter
President: Jackie Parrish
E-mail: INchapter@umdf.org

ILLINOIS

★Chicago Area Chapter
President: Cherie Lawson
E-mail: ChicagoChapter@umdf.org
Ambassadors:
Luke or Leslie Kirby, Philo
Patti Bauer, Springfield
St. Louis Area Mito Group
Contacts: Hope Grover,
Victoria Helms,
& Keli Stone

IOWA

Iowa Mito Group
Contacts: Kim Novy, Des Moines
Darla Klein, Des Moines
Ambassador:
Ronda Eick, Northern Iowa

LOUISIANA

Ambassadors:
Mandy Poche, Baton Rouge
Anna Stewart, Bossier City
Chantel Wodey, Corington

MAINE

Ambassador:
Amber Taylor, Bangor

MARYLAND

★DC / Baltimore / Northern
Virginia Chapter
President: Sharon Goldin
E-mail: dcbaltimore@umdf.org

MASSACHUSETTS/ CONNECTICUT

New England Mito Group
Contact: National Office

MICHIGAN

Michigan Mito Group
Contact: Julie Scott, Novi
Ambassadors:
Carrie Gervasone, Fraser
Holly Worden, Lakeview

MINNESOTA

★Minneapolis/St. Paul Chapter
President: Kalynn Wendt
E-mail: MNChapter@umdf.org

MISSISSIPPI

Greater Jackson Mito Group
Contact: Julie Manley, Jackson

MISSOURI / KANSAS

Kansas City Mito Group
Contact: Theresa Edwards,
Kansas City
St. Louis Area Mito Group
Contacts: Hope Grover,
Victoria Helms,
& Keli Stone

NEW MEXICO

Ambassador:
Stephanie Cassady,
Albuquerque

UMDF Chapters, Mito Groups, and Ambassadors

NEW YORK

★New York Metro Chapter
President: Kim Zuzzolo
E-mail:
NYMetroChapter@umdf.org
Western New York Mito Group
Contacts: Linda Roesch, Buffalo
Jennifer Schwartzoff,
Buffalo

Ambassadors:
Jacqueline Perrotta, Albany
Lori Piccirilli, Binghamton
Kimberly Dedrick, Utica

NORTH CAROLINA

Tar Heel Mito Group
Contacts: Heather Baudet,
Raleigh Durham
Adriana Smith,
Raleigh Durham

Ambassadors:
Terry Holeman, Fayetteville
Jenny Hobbs, Winston-Salem

OHIO

★Ohio Chapter – North East
President: Darcy Zehe
E-mail: OHChapter@umdf.org
Central Ohio Mito Group
Contacts: Ruth Gerke
& Jody Thompson

Cincinnati Mito Group
Contacts: Amanda & Jason
Salensky

Ambassadors:
Chris & Alisa Rawski, Toledo

OREGON

Ambassador:
Kimberli Freiling, Monmouth

PENNSYLVANIA

★Delaware Valley Chapter
Contact: Laurel Smith
E-mail: DelValChapter@umdf.org
Erie Mito Group

Contact: Jessica Myers
Pittsburgh Mito Group
Contact: Kimberly Dojonovic

Ambassadors:
Kim Olenderski,
Central Pennsylvania
Daria Grabowski, Erie
Karen Wilson, Pittsburgh
(adults)

Heather Pallas, Pittsburgh
(children)

SOUTH CAROLINA

★Carolina Foothills Chapter
Contacts: Christy Koury
& Margaret Moore

E-mail:
carolinafoothills@umdf.org
Ambassador
Karis Mott, Chapin

TENNESSEE

★Middle Tennessee Chapter
President: Courtney Fellers
E-mail:
midtennchapter@umdf.org

Memphis Area Mito Group
Contact: Emily Culley
& Karrie LaCroix

TEXAS

★Houston Chapter
President:
Deb Schindler-Boultinghouse
E-mail:
HoustonChapter@umdf.org
North Texas Mito Group
Contact: Joshua Brewer
Ambassador:
Shamayn Kennedy, Wichita Falls

UTAH

Ambassador:
Laura McCluskey, Orem

VERMONT

Ambassador:
MaryBeth LeFevre, Vermont

VIRGINIA

Ambassadors:
Heather Meyer, Lynchburg
Molly McCaffrey Adams,
Richmond

WASHINGTON

Ambassador: Joy Krumdiack,
NW Washington

WISCONSIN

Ambassadors:
Jaqueline Bohne, Harshaw
Mindy Welhouse, Kimberly
Terilyn Musser, LaCrosse/Eau Claire
Karen Loftus, Milwaukee

INTERNATIONAL

Ambassadors:
Rob Ryan, Australia
John Carreiro,
British Columbia
Nilam Argawal, India
Saijad Haider, Pakistan
Anne Hansen, Norway &
Vidar Hunstad Vik, Norway
Rowland Dicker, United Kingdom
Keely Schellenberg, Winnipeg

YOUTH AMBASSADORS

Joe Wise, California
Emily Swinn, Georgia
Briana Garrldo, Hawaii
Haley Wroth, Massachusetts/
Connecticut
Alexandra Simonian, New York
Tyler Liebegott, Pennsylvania
Colleen Powell, Pennsylvania
Devin Shuman, Washington



HOPE. ENERGY. LIFE.

8085 Saltsburg Rd., Suite 201
Pittsburgh, PA 15239
Phone: 1.888.317.UMDF (*toll free*)
Phone: 412.793.8077
Fax: 412.793.6477
info@umdf.org
www.umdf.org